8
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Green Renal Replacement Therapy: Caring for the Environment

      Submit here before July 31, 2024

      About Blood Purification: 3.0 Impact Factor I 5.6 CiteScore I 0.83 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Effects of Erythropoietin Treatment on Thyroid Dysfunction in Hemodialysis Patients with Renal Anemia

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The thyroid function was evaluated before and after 6 months of recombinant human erythropoietin (rhEPO) treatment (1,500-9,000 U/week) in 22 hemodialysis patients with hematocrit levels < 25%. Based upon the changes in hematocrit following rhEPO treatment, the patients were divided into two groups: 11 patients with an increase of the hematocrit level > 5% (group I) and 11 patients with an increase < 5% (group II). Before rhEPO administration, the levels of thyroid hormones, especially free thyroxine (T<sub>4</sub>) and free triiodothyronine (T<sub>3</sub>), were below the normal range despite normal thyrotropin values in most of the patients (low T<sub>4</sub>:7 cases in group I and 9 in group II; low T<sub>3</sub>:10 cases in group I and 10 in group II). RhEPO treatment significantly increased both total amount and free fractions of thyroid hormones in group I, whereas it did not affect these values in group II. Consequently, the pretreatment low T<sub>4</sub> or low T<sub>3</sub> status was resolved in a substantial number of the patients in group I (low T<sub>4</sub>:5 cases, low T<sub>3</sub>:4 cases). In addition, there was a significant correlation between the increases in hematocrit and free T<sub>3</sub> in all studied subjects (r = 0.603; p < 0.05). These results suggest that anemia may participate to some extent in the pathogenesis of thyroid dysfunction in hemodialysis patients with renal anemia.

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          1660-8151
          2235-3186
          1994
          1994
          16 December 2008
          : 66
          : 3
          : 307-311
          Affiliations
          2nd Department of Internal Medicine, Toyma Medical and Pharmaceutical University, Toyama, Japan
          Article
          187828 Nephron 1994;66:307–311
          10.1159/000187828
          8190183
          68240aa0-de61-41fe-91a5-0a3234a5d2a1
          © 1994 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          : 14 April 1993
          Page count
          Pages: 5
          Categories
          Original Paper

          Cardiovascular Medicine,Nephrology
          Erythropoietin,Hemodialysis,Thyroid function
          Cardiovascular Medicine, Nephrology
          Erythropoietin, Hemodialysis, Thyroid function

          Comments

          Comment on this article